 |
|
 |
- November 20, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Vascular Actions of Oral Hypoglycaemic Agents (Sulphonylureas, Biguanides and Glitazones) Related to Atherosclerosis"Dr. Peter Little (biography)
English - 2005-06-18 - 47 minutes
|
 | (30 slides) |
Summary :
In this presentation Dr. Little talks about the cellular and biochemical mechanisms of atherosclerosis, and pathways for the development of drugs to prevent cardiovascular disease (CVD) in diabetes.
As seen in the Steno-2 trial, an intensive broad spectrum therapy is important for reducing CVD in patients with diabetes, however there still remains a substantial amount of residual CVD (1).
There are lipid-dependent and -independent mechanisms of atherosclerosis. Dr. Little presents in vitro data collected by his group showing the effects of sulphonylureas, biguanides and glitazones on proteoglycan synthesis and LDL binding to vascular proteoglycans, and the effects of sulphonylureas, biguanides and glitazones (2) on vascular smooth muscle cell proliferation, as it might relate to restenosis following angioplasty.
Dr. Little ends the presentation with a discussion of which biochemical markers of inflammation and vascular disease could be used to initiate or monitor therapy directed at vascular disease, and data showing the ability of glitazones to lower blood levels of some of these markers.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Cellular and biochemical mechanisms of atherosclerosis
- The effects of OHAs on atherosclerosis and restenosis:
----> Cholesterol binding to matrix proteoglycans
----> VSMC proliferation
Bibliographic references :
1. Peter Gæde, M.D., Pernille Vedel, M.D., Ph.D., Nicolai Larsen, M.D., Ph.D., Gunnar V.H. Jensen, M.D., Ph.D., Hans-Henrik Parving, M.D., D.M.Sc., and Oluf Pedersen, M.D., D.M.Sc.Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes N Engl J Med. 2003 Jan 30;348(5):383-93.
2. Stephanie T. de Dios, BAppSC(Hons); Dennis Bruemmer, MD; Rodney J. Dilley, PhD; Melanie E. Ivey, BAppSci; Garry L.R. Jennings, MBBS, PhD; Ronald E. Law, PhD; Peter J. Little, PhD Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor- Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation Circulation. 2003;107:2548.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
